Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.51 |
| ▸ | DRD3 | P35462 | 10/20 | 0.51 |
| ▸ | DRD4 | P21917 | 4/20 | 0.51 |
| ▸ | HTR1A | P08908 | 4/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654785 | 0.94 | DRD2 (0.54) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL5654212 | 0.93 | DRD2 (0.55) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL5657822 | 0.93 | DRD2 (0.56) | DRD2DRD4HTR1ASLC6A2SLC6A3 | |
| SCHEMBL5657246 | 0.87 | DRD2 (0.65) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL5657324 | 0.87 | TSHR (0.52) | DRD2DRD3DRD4HTR1AADRA1A | |
| SCHEMBL5656889 | 0.85 | PTPN11 (0.58) | DRD2DRD4PTPN11ALDH1A1TSHR | |
| SCHEMBL5657836 | 0.85 | HTR1A (0.60) | DRD2DRD4HTR1APTPN11ALDH1A1 | |
| SCHEMBL5655876 | 0.84 | NOTUM (0.52) | DRD2DRD4HTR1AADRA1DADRA1A | |
| SCHEMBL5655729 | 0.83 | PTPN11 (0.58) | DRD2DRD3DRD4HTR1ASLC6A2 | |
| SCHEMBL5654681 | 0.81 | DRD2 (0.61) | DRD2DRD3DRD4HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074796-B2 | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2006-07-11 | — | — | US | claimed |
| EP-1464641-B1 | 4-Phenyl-piperazinyl, -piperidinyl and tetrahydropyridyl derivatives as dopamine D4 antagonists | LUNDBECK & CO AS H (DK) | 2008-05-14 | — | — | EP | disclosed |
| US-7223765-B2 | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2007-05-29 | — | — | US | disclosed |
| US-7074796-B2 | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2006-07-11 | — | — | US | disclosed |
| US-20060148815-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and-tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2006-07-06 | — | — | US | disclosed |
| EP-1464641-A1 | 4-Phenyl-piperazinyl, -piperidinyl and tetrahydropyridyl derivatives as dopamine D4 antagonists | H. Lundbeck A/S (DK) | 2004-10-06 | — | — | EP | disclosed |
| EP-1246817-B1 | 4-PHENYL-1-PIPERAZINYL, -PIPERIDINYL AND -TETRAHYDROPYRIDYL DERIVATIVES | LUNDBECK & CO AS H (DK) | 2004-06-23 | — | — | EP | disclosed |
| US-20030027832-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2003-02-06 | — | — | US | disclosed |
| US-20020193599-A1 | Dihydropyridines and new uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-19 | — | — | US | disclosed |
| EP-1246817-A1 | 4-PHENYL-1-PIPERAZINYL, -PIPERIDINYL AND -TETRAHYDROPYRIDYL DERIVATIVES | H. Lundbeck A/S (DK) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001049679-A1 | 4-PHENYL-1-PIPERAZINYL, -PIPERIDINYL AND -TETRAHYDROPYRIDYL DERIVATIVES | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148815-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and-tetrahydropyridyl derivatives | OPRD1, VDR, GPR4 | DRD2 27/4885DRD3 22/4885DRD4 10/4885 |
| US-20020193599-A1 | Dihydropyridines and new uses thereof | BPHL, BCKDK, DHCR7 | DRD2 1009/4885DRD3 373/4885DRD4 730/4885 |
| US-20030027832-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | OPRD1, DRD3, DRD2 | DRD2 3/4885DRD3 2/4885DRD4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.